AstraZeneca, Bristol Myers Squibb in $400bn talks
AstraZeneca and Bristol Myers Squibb discuss potential merger
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
AstraZeneca and Bristol Myers Squibb discuss potential merger
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.